全球神經血管設備市場 - 2025 - 2033

2023年，全球神經血管器械市場規模達38億美元，預計2033年將達84億美元，2025-2033年預測期間複合年成長率為9.4%。

神經血管設備是一種專門的醫療器械，旨在治療影響大腦和脊髓血管的疾病。這些設備主要用於與神經介入相關的手術，神經介入是介入放射學、神經病學和神經外科的一個分支，專注於診斷和治療各種神經血管疾病的微創技術。

神經血管裝置的主要目的是利用微創技術恢復血流、阻塞或移除異常血管，並預防或治療危及生命的疾病，如中風、腦出血和動脈瘤。這些設備旨在透過減少恢復時間、併發症和傳統開放性手術的需要來改善患者的治療效果。

在神經血管疾病日益流行和神經血管設備技術進步的推動下，神經血管設備市場正在經歷顯著成長。中風、腦動脈瘤和動靜脈畸形等疾病變得越來越常見，增加了對神經血管設備的需求。

例如，根據世界中風組織的數據，每年有超過 760 萬例新缺血性中風。在全球範圍內，超過 62% 的中風是缺血性中風。每年，超過 11% 的缺血性中風發生在 15-49 歲的人群中。每年，超過 58% 的缺血性中風發生在 70 歲以下的人群中。

此外，2024 年5 月，Penumbra, Inc. 宣布獲得CE 標誌批准，並在歐洲推出其三款神經血管再灌注導管Red 43、採用SendIt 技術的Red 72 和Red 78，用於治療急性缺血性中風。據 Penumbra 稱，這些設備最佳化了基於科學的血栓抽吸術（S-BAT），並採用最新的可追蹤性和抽吸技術進行設計，以解決各種大血管閉塞問題。

市場動態：

驅動程式和限制

神經血管設備不斷進步的技術

神經血管設備不斷進步的技術進步極大地推動了神經血管設備市場的成長，預計將在預測期內推動市場的成長。較新的神經血管裝置，例如分流器、支架回收器和栓塞線圈，其設計侵入性較小，可減少患者的恢復時間和併發症。例如，2024年8月，重力醫療科技推出了下一代中風治療設備：Neutron抽吸導管和Supernova支架取回器。早期採用已成功治療全球 60 多名患者。

此外，2024年6月，Terumo子公司MicroVention在美國推出了用於治療寬頸顱內動脈瘤的LVIS EVO腔內支撐裝置。毫米或5毫米的囊狀顱內動脈瘤。

該設備現在與增強的 2D 和 3D 成像技術整合，提供即時可視化來指導手術。此技術可幫助神經外科醫師更精確地放置設備，確保更安全、更有效的治療。

例如，2024 年 2 月，皇家飛利浦宣布對其影像導引治療系統 Azurion 進行重大改進，推出新型 Azurion 神經雙翼系統。新型介入系統旨在提高工作效率並幫助護理團隊更快地做出正確決策、治療更多患者並取得更好的結果，具有增強的 2D 和 3D 成像以及 X光探測器定位靈活性。新的影像導引治療系統是一個完整的介入解決方案，可為中風或其他神經血管疾病患者提供可靠的診斷、影像導引和治療評估

替代方案的可用性

替代治療方案的可用性是阻礙神經血管設備市場成長的關鍵因素之一。存在多種基於設備的干涉措施的替代方案，並且在許多情況下，由於成本效益、患者偏好和治療的侵入性較小等因素，這些替代方案是首選。

許多神經血管疾病，例如缺血性中風或腦動脈瘤，可以使用藥物而不是介入設備進行治療。抗血小板藥物（例如阿斯匹靈）和抗凝血劑（例如華法林、利伐沙班）等藥物治療可以預防血栓形成並降低中風或動脈瘤破裂的風險。例如，使用溶栓劑（例如組織纖溶酶原活化劑，tPA）治療急性缺血性中風通常可以減少對血栓切除術或其他基於設備的干涉措施的需求，從而限制對神經血管設備的需求。

在某些情況下，傳統的開放性手術仍然是首選，特別是對於複雜或大型動脈瘤和動靜脈畸形（AVM）。儘管開放式手術不如微創方法常用，但它可以被視為一種更成熟、更可靠的選擇。例如，對於患有巨大或難以治療的腦動脈瘤的患者，可能會建議進行夾閉手術，而不是栓塞或血流改道，這會減少神經血管裝置的市場佔有率。

有時，立體定位放射手術或雷射消融等替代方法是治療腦腫瘤、動靜脈畸形和其他血管病變的首選方法。與傳統的神經血管手術相比，這些方法風險較低，侵入性也較小。例如，伽瑪刀放射外科手術經常用作動靜脈畸形栓塞或手術切除的替代方法，特別是對於小病變。

目錄

第1章：市場介紹和範圍

• 報告的目標
• 報告範圍和定義
• 報告範圍

第 2 章：高階主管見解與要點

• 市場亮點和戰略要點
• 主要趨勢和未來預測
• 按產品類型分類的片段
• 按應用程式片段
• 最終使用者的片段
• 按地區分類的片段

第 3 章：動力學

• 影響因素
  • 促進要素
    • 神經血管設備不斷進步的技術
  • 限制
    • 替代方案的可用性
  • 機會
  • 影響分析

第 4 章：策略洞察與產業展望

• 市場領導者和先驅
  • 新興先鋒和傑出參與者
  • 擁有最大銷售品牌的知名領導者
  • 擁有成熟產品的市場領導者
• 新興新創企業和主要創新者
• CXO 觀點
• 最新進展和突破
• 案例研究/正在進行的研究
• 監管和報銷情況
  • 北美洲
  • 歐洲
  • 亞太地區
  • 拉丁美洲
  • 中東和非洲
• 波特五力分析
• 供應鏈分析
• 專利分析
• SWOT分析
• 未滿足的需求和差距
• 市場進入和擴張的推薦策略
• 情境分析：最佳情況、基本情況和最壞情況預測
• 定價分析和價格動態

第 5 章：神經血管設備市場，依產品類型

• 腦栓塞及動脈瘤彈簧圈裝置
  • 栓塞彈簧圈
  • 分流裝置
  • 液態栓塞劑
• 腦血管成形術和支架系統
  • 頸動脈支架
  • 栓塞保護系統
• 神經血栓切除裝置
  • 血塊回收裝置
  • 抽吸裝置/抽吸導管
  • 血管圈套器
• 支援設備
  • 微導管
  • 微型導絲
• 跨徑向接入設備

第 6 章：神經血管設備市場（依應用）

• 腦動脈瘤
• 缺血性中風
• 頸動脈狹窄
• 其他

第 7 章：神經血管設備市場（依最終用戶）

• 醫院
• 專科診所
• 手術中心
• 研究實驗室和學術機構
• 門診手術中心

第 8 章：神經血管設備市場，按區域市場分析和成長機會

• 北美洲
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲
  • 德國
  • 英國
  • 法國
  • 西班牙
  • 義大利
  • 歐洲其他地區
• 南美洲
  • 巴西
  • 阿根廷
  • 南美洲其他地區
• 亞太
  • 中國
  • 印度
  • 日本
  • 韓國
  • 亞太其他地區
• 中東和非洲

第 9 章：競爭格局與市場定位

• 競爭概況和主要市場參與者
• 市佔率分析與定位矩陣
• 策略夥伴關係、併購
• 產品組合和創新的主要發展
• 公司基準化分析

第 10 章：公司簡介

• Medtronic plc
• 公司概況
• 產品組合和描述
• 財務概覽
• 主要進展
• SWOT分析
• Stryker Corporation
• Terumo Corporation
• MicroPort Scientific Corporation
• Johnson & Johnson
• Penumbra, Inc.
• ASAHI INTECC USA, INC.
• Acandis GmbH
• Rapid Medical
• NeuroVasc Technologies, Inc.

第 11 章：假設與研究方法

• 資料收集方法
• 數據三角測量
• 預測技術
• 數據驗證和確認

第 12 章：附錄

The global neurovascular devices market reached US$ 3.8 billion in 2023 and is expected to reach US$ 8.4 billion by 2033, growing at a CAGR of 9.4% during the forecast period 2025-2033.

Neurovascular devices are specialized medical instruments designed to treat conditions affecting the blood vessels of the brain and spinal cord. These devices are primarily used in procedures related to neurointervention, a branch of interventional radiology, neurology and neurosurgery, which focuses on minimally invasive techniques for diagnosing and treating various neurovascular diseases.

The main purpose of neurovascular devices is to restore blood flow, block or remove abnormal blood vessels, and prevent or treat life-threatening conditions like strokes, brain hemorrhages and aneurysms, using minimally invasive techniques. These devices aim to improve patient outcomes by reducing recovery time, complications, and the need for traditional open surgeries.

The neurovascular devices market is experiencing significant growth, driven by the increasing prevalence of neurovascular disorders and technological advancements in neurovascular devices. Conditions such as stroke, cerebral aneurysms, and arteriovenous malformations are becoming more common, increasing the demand for neurovascular devices.

For instance, according to the World Stroke Organization, there are over 7.6 million new ischaemic strokes each year. Globally, over 62% of all incident strokes are ischaemic strokes. Each year, over 11% of all ischaemic strokes occur in people 15-49 years of age. Each year, over 58% of all ischaemic strokes occur in people under 70 years of age.

Additionally, in May 2024, Penumbra, Inc. announced the CE Mark approval and the launch in Europe of three of its neurovascular reperfusion catheters Red 43, Red 72 with SendIt technology, and Red 78 for the treatment of acute ischemic stroke. According to Penumbra, the devices optimize science-based aspiration thrombectomy, or S-BAT, and are engineered with the latest technology in trackability and aspiration to address a wide range of large vessel occlusions.

Market Dynamics: Drivers & Restraints

Rising technological advancements in neurovascular devices

The rising technological advancements in neurovascular devices are significantly driving the growth of the neurovascular devices market and are expected to drive the market over the forecast period. Newer neurovascular devices, such as flow diverters, stent retrievers and embolic coils, are designed to be less invasive, reducing recovery times and complications for patients. For instance, in August 2024, Gravity Medical Technology launched its next-generation stroke treatment devices: the Neutron aspiration catheter and the Supernova stent retriever. Early adoption has demonstrated the successful treatment of more than 60 patients worldwide.

Additionally, in June 2024, Terumo subsidiary MicroVention launched its LVIS EVO intraluminal support device to treat wide neck intracranial aneurysms in the U.S. The device is indicated for usage with neurovascular embolization coils in adults to treat saccular intracranial aneurysms with a neck width of 4 mm or greater or a dome-to-neck ratio of less than two that arise from a parent vessel with a diameter between 2 and 4.5 mm.

Devices now integrate with enhanced 2D and 3D imaging technologies, providing real-time visualization to guide procedures. This technology helps neurosurgeons place devices more precisely, ensuring safer and more effective treatments.

For instance, in February 2024, Royal Philips announced major enhancements to its Image Guided Therapy System, Azurion, with the launch of its new Azurion neuro biplane system. Designed to improve productivity and help care teams make the right decisions faster, treat more patients, and achieve better outcomes, the new interventional system features enhanced 2D and 3D imaging and X-ray detector positioning flexibility. The new image-guided therapy system is a complete interventional solution for confident diagnosis, image guidance, and therapy assessment of patients with stroke or other neurovascular diseases

Availability of alternatives

The availability of alternative treatment options is one of the key factors that can hamper the growth of the neurovascular devices market. Several alternatives to device-based interventions exist, and in many cases, these alternatives are preferred due to factors such as cost-effectiveness, patient preference and the less invasive nature of the treatments.

Many neurovascular disorders, such as ischemic stroke or cerebral aneurysms, can be treated using medications rather than interventional devices. Pharmacological treatments like antiplatelet drugs (e.g., aspirin) and anticoagulants (e.g., warfarin, rivaroxaban) can prevent clot formation and reduce the risk of stroke or aneurysm rupture. For instance, the use of thrombolytics (e.g., tissue plasminogen activator, tPA) for acute ischemic stroke can often reduce the need for thrombectomy or other device-based interventions, thus limiting demand for neurovascular devices.

In some situations, traditional open surgery remains the preferred option, especially for complex or large aneurysms and arteriovenous malformations (AVMs). Although less commonly used than minimally invasive methods, open surgery can be seen as a more established and reliable option. For instance, for patients with large or difficult-to-treat brain aneurysms, clipping surgery may be recommended over embolization or flow diversion, which can reduce the market share of neurovascular devices.

Alternatives like stereotactic radiosurgery or laser ablation are sometimes preferred for treating brain tumors, arteriovenous malformations, and other vascular lesions. These methods can offer less risk and are less invasive than traditional neurovascular procedures. For instance, Gamma Knife radiosurgery is frequently used as an alternative to embolization or surgical resection for AVMs, particularly for small lesions.

Segment Analysis

The global neurovascular devices market is segmented based on product type, application, end-user and region.

Product Type:

The cerebral angioplasty and stenting systems segment is expected to dominate the neurovascular devices market share

Over the years, technological advancements in angioplasty and stenting systems have improved treatment efficacy, safety and patient outcomes. The development of self-expanding stents, drug-eluting stents and balloon angioplasty systems has enhanced the precision and success rates of neurovascular procedures.

For instance, in June 2023, Fluid Biomed Inc. announced the World's first implantation of a polymer-based neurovascular stent in human patients, REDIRECT, its first-in-human clinical trial. Phase 1 of this technical feasibility and safety study has begun with successful device implantation without adverse effects in human subjects at the pre-determined 30-day time point and recruitment is ongoing.

Cerebral angioplasty and stenting are minimally invasive procedures, which are preferred by both patients and physicians because they involve smaller incisions, reduced recovery times, and fewer complications compared to traditional open surgeries. For instance, Angioplasty with stenting for carotid artery disease is performed through a small incision in the groin, making it a less traumatic alternative to surgery. This less invasive nature drives higher adoption of stenting systems in treating neurovascular diseases.

Endovascular treatments, such as cerebral angioplasty and stenting, are increasingly becoming the first line of treatment for neurovascular disorders due to their effectiveness and reduced risks compared to open surgery. This shift in preference is contributing to the dominance of the segment.

Geographical Analysis

North America is expected to hold a significant position in the neurovascular devices market share

North America especially the United States, is a hub for innovation in medical devices, with leading companies such as Medtronic, Stryker Corporation, Terumo Corporation and other leading players developing new and improved neurovascular devices. This includes the development of stent retrievers, flow diverters and clot removal devices that are highly effective in treating stroke and aneurysms.

For instance, in February 2024, CERENOVUS, Inc., part of Johnson & Johnson MedTech, launched CEREGLIDE 71 Intermediate Catheter, a next-generation intermediate catheter with TruCourse indicated for the revascularization of patients suffering from acute ischemic stroke. CEREGLIDE 71 Intermediate Catheter is the latest innovation in a planned CEREGLIDE Family of Catheters to join the CERENOVUS STROKE SOLUTIONS portfolio and is optimized for effective direct aspiration and for the delivery of compatible stent retrievers, including the EMBOTRAP III Revascularization Device, into the neurovasculature.

Asia-Pacific is growing at the fastest pace in the neurovascular devices market

The Asia Pacific region has a growing incidence of stroke, aneurysms, and carotid artery diseases due to lifestyle factors, rising levels of hypertension, smoking, and diabetes, which are risk factors for neurovascular conditions. For instance, the World Health Organization (WHO) reports that Asia, particularly China and India, has a high incidence of ischemic stroke, with nearly 70% of all strokes occurring in low- and middle-income countries in Asia. This significantly boosts the demand for neurovascular devices such as stents, coils, and thrombectomy systems.

There is an increasing awareness of minimally invasive neurovascular procedures such as stenting, angioplasty, and thrombectomy in the Asia Pacific region. As healthcare professionals and patients become more informed about the benefits of these procedures, the demand for neurovascular devices increases. For instance, the use of thrombectomy systems like the Solitaire FR Stent Retriever is growing in countries like India and China as part of the initiative to improve stroke treatment outcomes.

Competitive Landscape

The major global players in the neurovascular devices market include Medtronic plc, Stryker Corporation, Terumo Corporation, MicroPort Scientific Corporation, Johnson & Johnson, Penumbra, Inc., ASAHI INTECC USA, INC., Acandis GmbH, Rapid Medical, NeuroVasc Technologies, Inc. and among others.

Why Purchase the Report?

• Pipeline & Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
• Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
• Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
• Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
• Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
• Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
• Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
• Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
• Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
• Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
• Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
• Post-market Surveillance: Uses post-market data to enhance product safety and access.
• Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global neurovascular devices market report delivers a detailed analysis with 62 key tables, more than 57 visually impactful figures, and 179 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024

• Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
• Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
• Supply Chain: Distribution and Supply Chain Managers.
• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
• Academic & Research: Academic Institutions.

Table of Contents

1. Market Introduction and Scope

• 1.1. Objectives of the Report
• 1.2. Report Coverage & Definitions
• 1.3. Report Scope

2. Executive Insights and Key Takeaways

• 2.1. Market Highlights and Strategic Takeaways
• 2.2. Key Trends and Future Projections
• 2.3. Snippet by Product Type
• 2.4. Snippet by Application
• 2.5. Snippet by End-User
• 2.6. Snippet by Region

3. Dynamics

• 3.1. Impacting Factors
  • 3.1.1. Drivers
    • 3.1.1.1. Rising Technological Advancements in Neurovascular Devices
  • 3.1.2. Restraints
    • 3.1.2.1. Availability of Alternatives
  • 3.1.3. Opportunity
  • 3.1.4. Impact Analysis

4. Strategic Insights and Industry Outlook

• 4.1. Market Leaders and Pioneers
  • 4.1.1. Emerging Pioneers and Prominent Players
  • 4.1.2. Established leaders with largest selling Brand
  • 4.1.3. Market leaders with established Product
• 4.2. Emerging Startups and Key Innovators
• 4.3. CXO Perspectives
• 4.4. Latest Developments and Breakthroughs
• 4.5. Case Studies/Ongoing Research
• 4.6. Regulatory and Reimbursement Landscape
  • 4.6.1. North America
  • 4.6.2. Europe
  • 4.6.3. Asia Pacific
  • 4.6.4. Latin America
  • 4.6.5. Middle East & Africa
• 4.7. Porter's Five Force Analysis
• 4.8. Supply Chain Analysis
• 4.9. Patent Analysis
• 4.10. SWOT Analysis
• 4.11. Unmet Needs and Gaps
• 4.12. Recommended Strategies for Market Entry and Expansion
• 4.13. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
• 4.14. Pricing Analysis and Price Dynamics

5. Neurovascular Devices Market, By Product Type

• 5.1. Introduction
  • 5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 5.1.2. Market Attractiveness Index, By Product Type
• 5.2. Cerebral Embolization and Aneurysm Coiling Devices*
  • 5.2.1. Introduction
  • 5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 5.2.3. Embolic Coils
  • 5.2.4. Flow Diversion Devices
  • 5.2.5. Liquid Embolic Agents
• 5.3. Cerebral Angioplasty and Stenting Systems
  • 5.3.1. Carotid Artery Stents
  • 5.3.2. Embolic Protection Systems
• 5.4. Neurothrombectomy Devices
  • 5.4.1. Clot Retrieval Devices
  • 5.4.2. Suction Devices/Aspiration Catheters
  • 5.4.3. Vascular Snares
• 5.5. Support Devices
  • 5.5.1. Micro Catheters
  • 5.5.2. Micro Guidewires
• 5.6. Trans Radial Access Devices

6. Neurovascular Devices Market, By Application

• 6.1. Introduction
  • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 6.1.2. Market Attractiveness Index, By Application
• 6.2. Cerebral Aneurysms*
  • 6.2.1. Introduction
  • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 6.3. Ischemic Stroke
• 6.4. Carotid Artery Stenosis
• 6.5. Others

7. Neurovascular Devices Market, By End-User

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 7.1.2. Market Attractiveness Index, By End-User
• 7.2. Hospitals*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Specialty Clinics
• 7.4. Surgical Centers
• 7.5. Research Laboratories and Academic Institutes
• 7.6. Ambulatory Surgical Centers

8. Neurovascular Devices Market, By Regional Market Analysis and Growth Opportunities

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 8.1.2. Market Attractiveness Index, By Region
• 8.2. North America
  • 8.2.1. Introduction
  • 8.2.2. Key Region-Specific Dynamics
  • 8.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 8.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 8.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 8.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 8.2.6.1. U.S.
    • 8.2.6.2. Canada
    • 8.2.6.3. Mexico
• 8.3. Europe
  • 8.3.1. Introduction
  • 8.3.2. Key Region-Specific Dynamics
  • 8.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 8.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 8.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 8.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 8.3.6.1. Germany
    • 8.3.6.2. U.K.
    • 8.3.6.3. France
    • 8.3.6.4. Spain
    • 8.3.6.5. Italy
    • 8.3.6.6. Rest of Europe
• 8.4. South America
  • 8.4.1. Introduction
  • 8.4.2. Key Region-Specific Dynamics
  • 8.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 8.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 8.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 8.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 8.4.6.1. Brazil
    • 8.4.6.2. Argentina
    • 8.4.6.3. Rest of South America
• 8.5. Asia-Pacific
  • 8.5.1. Introduction
  • 8.5.2. Key Region-Specific Dynamics
  • 8.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 8.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 8.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 8.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 8.5.6.1. China
    • 8.5.6.2. India
    • 8.5.6.3. Japan
    • 8.5.6.4. South Korea
    • 8.5.6.5. Rest of Asia-Pacific
• 8.6. Middle East and Africa
  • 8.6.1. Introduction
  • 8.6.2. Key Region-Specific Dynamics
  • 8.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 8.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 8.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

9. Competitive Landscape and Market Positioning

• 9.1. Competitive Overview and Key Market Players
• 9.2. Market Share Analysis and Positioning Matrix
• 9.3. Strategic Partnerships, Mergers & Acquisitions
• 9.4. Key Developments in Product Portfolios and Innovations
• 9.5. Company Benchmarking

10. Company Profiles

• 10.1. Medtronic plc*
  • 10.1.1. Company Overview
  • 10.1.2. Product Portfolio and Description
  • 10.1.3. Financial Overview
  • 10.1.4. Key Developments
  • 10.1.5. SWOT Analysis
• 10.2. Stryker Corporation
• 10.3. Terumo Corporation
• 10.4. MicroPort Scientific Corporation
• 10.5. Johnson & Johnson
• 10.6. Penumbra, Inc.
• 10.7. ASAHI INTECC USA, INC.
• 10.8. Acandis GmbH
• 10.9. Rapid Medical
• 10.10. NeuroVasc Technologies, Inc.

LIST NOT EXHAUSTIVE

11. Assumption and Research Methodology

• 11.1. Data Collection Methods
• 11.2. Data Triangulation
• 11.3. Forecasting Techniques
• 11.4. Data Verification and Validation

12. Appendix

• 12.1. About Us and Services
• 12.2. Contact Us